Actuate Therapeutics Shows 38% Reduction in Risk of Death in Phase 2 Pancreatic Cancer Trial—Long-Term Survival Data Impresses at ASCO GI 2026
Market Chameleon (Mon, 12-Jan 9:14 AM)
